Today's Top Gainer
| SYMBOL | CMP | Chg (%) |
|---|---|---|
Note:Top Gainer - Nifty 50 More
Natco Pharma Ltd - Share Price
NATCOPHARM
Financials
News & Updates
Natco Pharma gets USFDA approval for lmatinib Mesylate Tablets
Mar 06,2019 12:06 PM
Natco Pharma gets USFDA approval for lmatinib Mesylate Tablets
Natco, partner Lupin receives approval for lmatinib Mesylate Tablets Mar 06,2019
Board of Natco Pharma recommends Second Interim Dividend Feb 12,2019
Natco Pharma to conduct board meeting Feb 02,2019
Natco Pharma, Alvogen file ANDA for Ibrutinib tablets for US markets Jan 31,2019
NATCO launches Valsartan-Sacubitril tablet in India Jan 28,2019
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | 463.20 | 139.61 | 110,873.27 | -38.68 | 0.43 | 2,192.41 | 77.62 |
| Piramal Enterprises Ltd | 2,649.85 | 69.99 | 48,951.30 | -67.47 | 0.92 | 890.35 | 1,086.74 |
| Dr Reddys Laboratories Ltd | 2,799.10 | 37.18 | 46,513.41 | 399.40 | 0.71 | 2,718.20 | 725.76 |
| Aurobindo Pharma Ltd | 789.55 | 33.45 | 46,102.77 | 463.51 | 0.48 | 3,160.50 | 180.71 |
| Divis Laboratories Ltd | 1,724.35 | 35.10 | 45,803.95 | 379.49 | 0.58 | 1,342.92 | 237.46 |
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Summary & Reports
No Company Summary found
Registered Office
Natco House,Road No 2 Banjara Hills,Hyderabad, Telangana,500033
Tell. : +91-040-23547532
Website : http://www.natcopharma.co.in
Email : investors@natcopharma.co.in
Registrar Office
12-10-167, Bharath Nagar, Hyderbad - 500018 INDIA
Tell. : +91-040-23818475/76/2
Website : www.vccilindia.com
Email : info@vccilindia.com
Reports by natco-pharma-ltd
Latest Release by natco-pharma-ltd
Result Express
Natco Pharma Ltd's Q2FY19 consolidated net profit rises 115.17% yoy to Rs181.60cr : Misses Estimates
Apr 21, 2019 07:37 AM
The company’s consolidated revenue stood at Rs543.50cr, up 27.37% yoy and 0.91% qoq.
Shareholding Snapshot
Loading ...
| Mar - 2019 | |
|---|---|
| Promoter | - |
| Foreign | 1.33% |
| Indian | 47.38% |
| Total Promoter | 48.71% |
| Non Promoter | - |
| Institutions | 28.53% |
| Non-Institutions | 22.77% |
| Total Non-Promoter | 51.29% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
Dividend
Annc. Date
12 Feb 2019
Effective. Date
21 Feb 2019
Divi. Type
Interim 2
Divi.(%)
175
Divi. Amt.
3.5
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on ... More
Purpose
Board Meeting
Exp. Date
12 Feb 2019
Annc. Date
02 Feb 2019
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is sched... More
